Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"In this era of personalized cancer treatment, we are quite excited about this trial," said Dr. Villalona-Calero. "Although we have had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potential to target K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy."

"This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical setting," said Dr. Brad Thompson, President and CEO of Oncolytics. "Assuming we achieve an acceptable response rate, the combination of REOLYSIN(R) with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies."

This trial is a single arm, two-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The report on the Global ... the concerned market for revenue forecasts and market trends. ... of 51.9% from 2013 to 2018. At the projected ... of $1,415.6 million by 2018. , Browse through the ... for information about the market segmentation and in-depth analysis ...
(Date:11/26/2014)... 2014 In keeping with the holiday ... bevy of last-minute Thanksgiving savings. The company is offering ... all product lines this holiday weekend as well as ... Friday, and Cyber Monday are right around the corner, ... both loyal customers and those looking to explore their ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... PMG Research, Inc. announced today ... a network of sites that provide clinical research services to ... patient lives through its partnerships with large physician practices and ... site locations in the Southeastern United States and spans over ... board will be held by: Dr. Robert Holmes, ...
Breaking Biology Technology:Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... , , , ... of hospital-related infections in the U.S. costs up to $11 billion a ... implanted in patients. Until now, efforts to control drug-resistant biofilms on such ... mats developed by collaborators Pat Mather and Dacheng Ren of the Syracuse ...
... ... announced the PX14400 high-speed digitizer, the industry,s most advanced wideband and high dynamic ... when using the programmable gain amplifier in 1 dB steps for maximum gain ... is employed for the cleanest possible signal path to the ADC. 1 GB ...
... /PRNewswire/ - Enerkem, a leading waste-to-biofuels and green chemicals ... by its partners, the City of Edmonton and the ... on their joint advanced energy research facility. The ceremony ... Advanced Education and Technology in Alberta, and the Edmonton ...
Cached Biology Technology:New Antimicrobial Webs Sterilize Medical Implants for 14 Days 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 3Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 4Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 2Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 3
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2The tiger beetle: Too fast to see 2
... YORK, Feb. 17, 2011 A research group led by ... genetic variant that allows a fish in the Hudson River ... study published in the February 18, 2011, online issue of ... River fish apparently evolved rapidly in response to the toxic ...
... work. Researchers at Rochester Institute of Technology are ... is doubly "green" because algae consume nitrates and phosphates ... end result: clean wastewater and stock for a promising ... into receiving bodies of water at treatment plants, while ...
... research could eventually lead to new approaches for controlling ... which are caused by trypanosomes carried by the bloodsucking ... reproduction evolved very early and is now ubiquitous in ... living organisms except bacteria). However, real evidence is ...
Cached Biology News:A genetic mutation allows Hudson River fish to adapt to PCBs 2The green machine: Algae clean wastewater, convert to biodiesel 2Shining a light on trypanosome reproduction 2
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
... This kit is designed to knockout or alter ... less than one week. Red/ET recombination allows the ... precise, specific, and faithful manner. An FRT-flanked kanamycin ... which can be used to replace a gene ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... LIGHT. Useful in cell activation experiments when calcium dose-response ... Soluble in DMSO or EtOH. For use ... in DMSO is recommended. Microliter amounts of this solution ... mixing (e.g. 10 μl into 5 ml of H ...
Biology Products: